The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Infigratinib in previously treated advanced CCA
Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, presents the final results from a Phase II study of infigratinib, an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion or rearrangement. Infigratinib is associated with promising anticancer activity and a manageable safety profile in this patient population and a Phase III study is ongoing. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
